FDA Orange Book · active-ingredient family
Desvenlafaxine succinate
Desvenlafaxine succinate: 1 brand, 11 generics; first approved Feb 29, 2008; generic available.
Generic availableHas discontinued products
Generic status & protection
Generic available: 11 ANDA applications approved.
Earliest patent expiry
Brands (NDA)
1
Generics (ANDA)
11
Listed patents
1
Next patent expiry
Jul 05, 2027
in 11 mo
Brand (NDA) products
Originator applications
- PRISTIQRLDPF PRISM CVNDA 02199220143 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 50MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 100MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 25MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB
Generic (ANDA) products (11)
Abbreviated applications
- DESVENLAFAXINE SUCCINATEYICHANG HUMANWELLANDA 22046020263 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 25MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 50MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 100MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB - DESVENLAFAXINE SUCCINATEMACLEODS PHARMS LTDANDA 21142720252 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 50MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 100MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB - DESVENLAFAXINE SUCCINATERUBICON RESEARCHANDA 20402820233 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 50MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 100MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 25MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB - DESVENLAFAXINE SUCCINATEZYDUS PHARMSANDA 20402020223 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 50MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 100MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 25MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB - DESVENLAFAXINE SUCCINATELUPINANDA 20417220223 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 50MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 100MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 25MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB - DESVENLAFAXINE SUCCINATEYICHANG HUMANWELLANDA 21001420203 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 50MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 100MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 25MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB - DESVENLAFAXINE SUCCINATEPLATINUMANDA 20480520192 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 50MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 100MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB - DESVENLAFAXINE SUCCINATEALEMBICANDA 20400320183 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 50MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 100MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 25MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB - DESVENLAFAXINE SUCCINATEACTAVIS LABS FLANDA 20406520163 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 25MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 50MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 100MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB - DESVENLAFAXINE SUCCINATEHIKMAANDA 20408320163 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 100MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 25MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB EQ 50MG BASE TABLET, EXTENDED RELEASE ORAL Rx AB - DESVENLAFAXINE SUCCINATEPHARMOBEDIENTANDA 20409520152 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 50MG BASE TABLET, EXTENDED RELEASE ORAL Discontinued — EQ 100MG BASE TABLET, EXTENDED RELEASE ORAL Discontinued —
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Listed patents
Orange Book patent file
| Patent | Expires | In | Type |
|---|---|---|---|
| 8269040 | in 11 mo | Substance |
Approval history
FDA approval span
First approval
18 yr 9 mo ago
Most recent approval
5 mo ago
Approvals span 2008–2026 across 12 FDA applications.
Brand (NDA) 18%
Generic (ANDA) 1192%
Desvenlafaxine succinate: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
